Due to the excellent prognosis, some authors affirm that it is possible to perform a conservative surgery in young women who have not fulfilled their reproductive desire, without having repercussions in terms of overall survival.

The objective of the study was to know the treatment and the overall survival of the Borderline Ovarian Tumors in young women.

Methodology A retrospective cohort study was conducted. The study period was from January 2012 to January 2020. A total of 131 women with Borderline Ovarian Tumors were included in the study. Information was collected about: demographic data, diagnosis, type of surgery performed, disease-free survival, and overall survival. Two cohorts were established: conservative treatment (n = 37) vs radical treatment (n = 94).

Result(s)* 131 women with a diagnosis of Borderline Ovarian Tumors were diagnosed, representing 16.7% of all the malignant ovarian tumors within this period (n = 784). 91.5% were diagnosed in Stage I according to the FIGO classification and the most histological line frequent was the mucinous (49.2%). The risk of global relapse was 6.2% and overall survival was 95.4%.

Regarding the group of patients who underwent conservative surgery, the risk of relapse was 13.5% (n = 5) compared to 3.2% (n = 3) in the group radical treatment, (p = 0.042).

The Overall survival was 100% in women with conservative surgery compared to radical surgery, 94.6%, (p = 0.130).

Conclusion* Borderline Ovarian Tumors present excellent prognosis, obtaining great positive results in overall survival regardless the performance of conservative surgery in young women with unfulfilled reproductive desire.

**SUCCESSFUL LIVE BIRTH TWINS AFTER CHEMOTHERAPY DUE CARCINOMA OF COLON DURING PREGNANCY: A CASE REPORT**

1BJocic Pivac*, 1V Kraic, 1J Milojic, 1GAK Narodni front, obgyn, Belgrade, Serbia; 2general hospital Lazarevac, obgyn, Belgrade, Serbia 10.1136/ijgc-2021-ESGO.241

Introduction/Background* Diagnosing cancer during pregnancy is uncommon. Approximately one in every 1000 pregnancies is diagnosed with cancer during the antenatal period. Cervical cancer and breast cancer are among the most commonly identified cancers during pregnancy but gastrointestinal, urological, and lung cancers have a lower rate of incidence.

In this case we discuss successful management of a patient who was diagnosed with carcinoma of ascendant colon during the antenatal period.

Methodology 42 years old women (PARA -0, GRAV -) was admitted in our hospital in 12 weeks gestations because of pain in abdomen. In previous history, before 4 years she had breast cancer surgery when a local tumorectomy was performed with chemotherapy in six cycles. The pregnancy occurred after IVF. She had all symptoms of hyperstimulation syndromes with big ovaries in diameter of 12 cm and ascites. She did not complain any gastrointestinal problem. After two weeks of therapy for hyperstimulation syndromes she had increasing abdominal pain. We performed laparotomy.

Result(s)* After opening the abdomen, we found a tumor of the ascending colon and performed a right hemicolectomy with bilateral ovariectomy. The omentum was full of metastases. We performed a colostomy. Her abdominal pain was lost after surgery. She received five cycle of chemotherapy of FOLOFOX. She was delivered by Caesarean section at the 33rd weeks of pregnancy. She was discharged on the seven postoperative day because of her good general condition, as well as that of her newborns, two girls.

Conclusion* Carcinoma and pregnancy bring us two main problems. One is to discover right diagnosis and the other is to choose optimal treatment because it requires considerations of both pregnant women and unborn fetus. Colorectal carcinomas are rare and definitive treatment depends on the term of pregnancy. Generally, definitive surgical therapy is offered if the diagnosis is made early in the pregnancy and deferred until after parturition if it made in the late pregnancy. In our case we performed even hysterectomy because of due to the advanced stage of the disease.

**537 FERTILITY SPARING TREATMENT IN PATIENTS WITH ENDOMETRIAL CANCER (FERT-ENC) FROM THE SPANISH INVESTIGATIONAL NETWORK GYNECOLOGIC ONCOLOGY GROUP**

1V Lago*, 1MT Marina Martin, 2M Lasca Modrego, 3B Gil Ibanez, 4R Rodriguez, 5J Domingo, 6E Minig, 7P Padilla Iserte, 8T Arencibia Sanchez, 9M Sola Ferichola, 10M Mumbiary, 11B Martin, 12L Iacopini, 13S Cabrera, 14P Coronado, 15U Utrilla Layna, 16G Salas, 17C Corbalan, 18S Domingo, 19University Hospital La Fe, Spain; 2Maternal and Child Hospital University of the Canaries; 3University Hospital 12 de Octubre; 4Clinic and University Hospital Virgen de la Arrixaca; 5IU Las Palmas; 6CEU Cardenal Herrera University; 7General University hospital of Alicante; 8Clinic University Hospital; 9Hospital Getafe; 10Hospital Quironsalud Madrid; 11Hospital Quironsalud Madrid, Gynecology., Pau de Alarcón, Spain; 12University hospital Vall d’Hebron; 13Clinic University Hospital San Carlos; 14University Hospital Fundación Jimenez Diaz; 15University Hospital La Rivera; 16University Hospital Torrecárdenas; 17University Hospital Los Arcos 10.1136/ijgc-2021-ESGO.242

Introduction/Background* The primary objective was to evaluate the response rate of conservative treatment in endometrial cancer and the secondary objective was to assess oncological, fertility and obstetric outcomes in fertility preservation patients.

Methodology This was a multi-centre, observational, retrospective study of endometrial cancer patients who underwent fertility-sparing treatment in Spanish centres (January 2010–2020). Seventy-three patients with stage IA, endometrioid adenocarcinoma of the uterus were included in the study.

Result(s)* The levonorgestrel intrauterine device (LNG-IUD) was the most used method (53.4%), followed by megestrol acetate (20.5%) and medroxyprogesterone acetate (16.4%). During the 24-month follow-up, the rate of complete response to the fertility-sparing management was 74% (n = 54/73) and 8.2% (n = 6/73) patients presented a partial response. Additionally, 13 (17.8%) patients presented with persistent disease and six (8.2%) patients relapsed after response. The use of LNG-IUD was associated with a higher complete response rate (LNG-IUD 87.2% vs. others 58.8%; p = 0.01). Surgical treatment (at least hysterectomy) was completed in 44 (60.3%) patients. Four (5.5%) patients presented with relapse after surgery being associated with it the final stage FIGO III (p = 0.036), myometrial invasion >